News
SNY
55.54
-1.26%
-0.71
Sanofi inks $1B deal to sell autoimmune disorder therapy
Seeking Alpha · 41m ago
Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules
Seeking Alpha · 1h ago
CORRECTED-EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show
Reuters · 2h ago
Deals of the day-Mergers and acquisitions
Reuters · 3h ago
UPDATE 1-Texas attorney general sues insulin makers and pharmacy middlemen over high costs
Reuters · 16h ago
Texas attorney general sues insulin makers and pharmacy middlemen over high costs
Reuters · 19h ago
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Seeking Alpha · 20h ago
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
Barchart · 21h ago
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity
Seeking Alpha · 21h ago
BNY Mellon International Equity Fund Q2 2024 Commentary
Seeking Alpha · 22h ago
Novavax: Lack Of Sustainable Revenue Growth Is A Problem
Seeking Alpha · 23h ago
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
TipRanks · 1d ago
Novavax stock rallies 15% following bullish Jefferies note
Seeking Alpha · 1d ago
World Organization For Animal Health Says Hungary And Italy Report Farm Outbreaks Of Highly Pathogenic H5N1 Bird Flu
Benzinga · 1d ago
Sanofi’s Dupixent Wins Groundbreaking Approval in China
TipRanks · 1d ago
Here's Why You Should Consider Buying Jazz Pharmaceuticals' Stock
NASDAQ · 1d ago
French and Benelux stocks-Factors to watch
Reuters · 2d ago
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
Benzinga · 2d ago
Sanofi seeks revised proposals for Opella, Bloomberg reports
TipRanks · 2d ago
Sanofi Is Said To Ask For Revised Bids For Unit In Coming Days
Benzinga · 2d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.